(Q46099770)

English

A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability

scientific article published on 5 March 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19262596

A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability (English)

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19262596

2

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19262596

author name string

B ten Cate

1

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19262596

M de Bruyn

3

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19262596

T Bijma

4

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19262596

D Samplonius

5

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19262596

M Schwemmlein

6

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19262596

G Huls

7

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19262596

G Fey

8

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19262596

W Helfrich

9

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19262596

publication date

5 March 2009

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19262596

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19262596

23

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19262596

8

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19262596

1389-1397

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19262596

https://scigraph.springernature.com/pub.10.1038/leu.2009.34

0 references

Drug therapy for acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.34

21 January 2018

Fifty years of clinical research by the leukemia committee of the cancer and leukemia group B.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.34

21 January 2018

The difficult problem of acute myeloid leukemia in the older adult

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.34

21 January 2018

Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.34

21 January 2018

Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.34

21 January 2018

Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.34

21 January 2018

Safety and antitumor activity of recombinant soluble Apo2 ligand

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.34

21 January 2018

Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.34

21 January 2018

Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.34

21 January 2018

Identification and characterization of a new member of the TNF family that induces apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.34

21 January 2018

Antitumor activity of bortezomib alone and in combination with TRAIL in human acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.34

21 January 2018

Simultaneous inhibition of epidermal growth factor receptor (EGFR) signaling and enhanced activation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-mediated apoptosis induction by an scFv:sTRAIL fusion protein with speci

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.34

21 January 2018

Exceptionally potent anti-tumor bystander activity of an scFv:sTRAIL fusion protein with specificity for EGP2 toward target antigen-negative tumor cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.34

21 January 2018

Target cell-restricted and -enhanced apoptosis induction by a scFv:sTRAIL fusion protein with specificity for the pancarcinoma-associated antigen EGP2.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.34

21 January 2018

Targeted delivery of a designed sTRAIL mutant results in superior apoptotic activity towards EGFR-positive tumor cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.34

21 January 2018

High level expression of tissue inhibitor of metalloproteinases in Chinese hamster ovary cells using glutamine synthetase gene amplification

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.34

21 January 2018

Dimeric and trimeric antibodies: high avidity scFvs for cancer targeting.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.34

21 January 2018

Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: a retrospective review.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.34

21 January 2018

Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.34

21 January 2018

Valproic acid inhibits proliferation and induces apoptosis in acute myeloid leukemia cells expressing P-gp and MRP1.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.34

21 January 2018

Heat shock protein 90 inhibition is cytotoxic to primary AML cells expressing mutant FLT3 and results in altered downstream signalling.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.34

21 January 2018

Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor-resistant acute myeloid leukemia cells.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.34

21 January 2018

Complete molecular remission in chronic myelogenous leukemia after imatinib therapy.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.34

21 January 2018

Mechanistic role of heat shock protein 70 in Bcr-Abl-mediated resistance to apoptosis in human acute leukemia cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.34

21 January 2018

Calicheamicin gamma 1I: an antitumor antibiotic that cleaves double-stranded DNA site specifically

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.34

7 January 2021

based on heuristic

inferred from DOI database lookup

The tumor necrosis factor-related apoptosis-inducing ligand receptors TRAIL-R1 and TRAIL-R2 have distinct cross-linking requirements for initiation of apoptosis and are non-redundant in JNK activation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.34

7 January 2021

based on heuristic

inferred from DOI database lookup

Target cell-restricted apoptosis induction of acute leukemic T cells by a recombinant tumor necrosis factor-related apoptosis-inducing ligand fusion protein with specificity for human CD7.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.34

7 January 2021

based on heuristic

inferred from DOI database lookup

A CD33-specific single-chain immunotoxin mediates potent apoptosis of cultured human myeloid leukaemia cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.34

7 January 2021

based on heuristic

inferred from DOI database lookup

Synthesis of high avidity antibody fragments (scFv multimers) for cancer imaging

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.34

7 January 2021

based on heuristic

inferred from DOI database lookup

Selective induction of apoptosis in leukemic B-lymphoid cells by a CD19-specific TRAIL fusion protein

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.34

7 January 2021

based on heuristic

inferred from DOI database lookup

Loss of CD20 expression in relapsed lymphomas after rituximab therapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.34

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/LEU.2009.34

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19262596

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19262596

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46099770&oldid=2092474754"